Sign in
CompletedPhase 4

Xofluza-Wearables Feasibility-Study

Key facts

Who runs it
Children's Hospital of Philadelphia
Where
Philadelphia, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 4
People taking part
498 people enrolled
Started
14 Dec 2023
Ended
30 Apr 2025
Type of study
Interventional, 4 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Baloxavir Marboxil
Record updated
11 July 2025

Who can take part

Age
2 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

  • Population 1: Potential Baloxavir treatment group (CHOP transplant subjects 5 years \& up)
  • Willing CHOP male or female kidney, heart, liver or lung single or multiple transplant recipients aged 5 years or older as per FDA guidelines
  • Willing to regularly wear a smartwatch and take an at-home positive respiratory virus (RV) panel which will include a diagnoses of Influenza A or B
  • Have an antigen positive diagnoses of Influenza A or B (a PCR-based positive clinical diagnoses of Influenza A or B may be requested in "alarm positive plus antigen positive but asymptomatic" cases)
  • Can be included if their treating physician prescribe prophylactic treatment of Baloxavir if the subject has been exposed to Influenza
  • If Baloxavir is prescribed the study subject should be treated within 48 hours of symptom onset (regardless of the alarming time); Population 2: Potential Baloxavir treatment group (CHOP waitlisted subjects 5 years \& up)
  • Willing waitlisted CHOP kidney, heart, liver or lung single or multiple transplant recipients aged 5 years or older, which are anticipated to have a transplant in the next 12 months; Population 3: Potential Baloxavir treatment group (non-transplanted household members)
  • Non-transplanted household member of a CHOP transplant recipient or waitlisted patient
  • Be at least 5 years of age
  • Willing to regularly wear a smartwatch and take an at-home positive respiratory virus (RV) panel for diagnoses of Influenza A or B
  • Have a Antigen-based positive diagnoses of Influenza A or B; Population 4: Non-Baloxavir treatment subjects
  • CHOP transplant recipients and all other non-transplanted household members who are 2-4 years of age
  • Subjects 5 years and up who are Influenza positive but whom do not receive Baloxavir treatment

Who cannot take part

  • Any allergy to Baloxavir (although they can remain in the study as an influenza case or control without Baloxavir treatment, or if they have been treated with a different medication for influenza) or a recommendation from the study physicians'/transplant pharmacist(s) not to take Baloxavir
  • If the subject is taking a prohibited medication. These include Influenza antiviral drugs with the exception of oseltamivir and baloxavir (such as peramivir, laninamivir, zanamivir, rimantadine, umifenovir or amantadine)
  • A household transplant recipient is not participating in the study
  • A recommendation from the study physicians'/transplant pharmacist not to take Baloxavir
  • If the subject is taking a prohibited medication. These include Influenza antiviral drugs with the exception of oseltamivir and baloxavir (such as peramivir, laninamivir, zanamivir, rimantadine, umifenovir or amantadine)
  • If the subject is pregnant or breast feeding at the time of early infection alerting
  • Any allergy to Baloxavir (although they will remain in the study as an influenza case/control without treatment)
  • If the subject is younger than 5 years of age
  • If the subject is younger than 5 years of age
  • Population 1:
  • Subjects weighing < 20 kg
  • If the subject is unable or unwilling to consent
  • If the subject requires mechanical ventilation at time of enrollment
  • Unwilling or unable to comply with the study requirements; Population 2: All exclusion criteria listed for Population 1; Population 3:
  • Subjects weighing < 20 kg
  • If the subject is unable or unwilling to consent
  • If the subject is pregnant at screening
  • Unwilling or unable to comply with the study requirements

Where in United States

  • Children's Hospital of PhiladelphiaPhiladelphia, United States

About the trial

What the trial wants to find out

The goal of this prospective, interventional, single-center study is to assess whether the early detection of Influenza with smart wearable device algorithms and alerting, rapid testing, and subsequent Baloxavir treatment demonstrate better post-infection outcomes versus publicly available- and Centers for Disease Control (CDC)-derived national statistics for equivalent household populations as well as pediatric kidney, heart, liver, lung transplant recipients and waitlisted patients.

The 4 groups in the trial

  • Population 1: Transplant RecipientsTreatment being tested

    Participants who are a CHOP kidney, heart, liver or lung single or multiple transplant recipients aged 5 years or older will receive a single dose of Baloxavir.

    Treatment: Baloxavir Marboxil

  • Population 2: Waitlisted Patients for TransplantTreatment being tested

    Participants who are waitlisted CHOP kidney, heart, liver or lung single or multiple transplant recipients aged 5 years or older will receive a single dose of Baloxavir marboxil.

    Treatment: Baloxavir Marboxil

  • Population 3: Household Members (Non-Transplant)Treatment being tested

    Non-Transplanted Household Members aged 5 years or older will receive a single dose of Baloxavir marboxil.

    Treatment: Baloxavir Marboxil

  • Population 4: Non-Baloxavir treatment subjectsNo study treatment, for comparison

    CHOP transplant recipients and all other non-transplanted household members who are 2-4 years of age. Subjects 5 years and up who are Influenza positive but whom do not receive Baloxavir treatment

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Feasibility Study of Xofluza Treatment of Influenza in Pediatric Transplant Recipients, Waitlisted Subjects and Household Members After Early Infection Alerting Using Wearable Devices
Record updated
11 July 2025